163258-24-0

Basic information

• Product Name: 5-(4-METHYLPHENOXY)-1H-INDOLE
• Synonyms: 5-(4-METHYLPHENOXY)-1H-INDOLE
• CAS NO: 163258-24-0
• Molecular Formula: C₁₅H₁₃NO
• Molecular Weight: 223
• Mol File: 163258-24-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 390.8±17.0 °C(Predicted)
• Appearance: /
• Density: 1.182±0.06 g/cm3(Predicted)
• PKA: 16.48±0.30(Predicted)
• CAS DataBase Reference: 5-(4-METHYLPHENOXY)-1H-INDOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-METHYLPHENOXY)-1H-INDOLE(163258-24-0)
• EPA Substance Registry System: 5-(4-METHYLPHENOXY)-1H-INDOLE(163258-24-0)

Safety Data

• Hazardous Substances Data: 163258-24-0(Hazardous Substances Data)

Upstream product

• 106-44-5 p-cresol 
• 1259448-37-7 4-(trimethylsilyl)-1H-indol-5-yl trifluoromethanesulfonate 
• 1259448-44-6 C₁₂H₁₄F₃NO₃SSi 
• 1953-54-4 indol-5-ol 
• 624-31-7 4-tolyl iodide 
• 163258-23-9 5-(4-methylphenoxy)indole-2-carboxylic acid 
• 10075-50-0 5-bromo-1H-indole 

Relevant articles and documents

Indolyne experimental and computational studies: Synthetic applications and origins of selectivities of nucleophilic additions

Efficient syntheses of 4,5-, 5,6-, and 6,7-indolyne precursors beginning from commercially available hydroxyindole derivatives are reported. The synthetic routes are versatile and allow access to indolyne precursors that remain unsubstituted on the pyrrole ring. Indolynes can be generated under mild fluoride-mediated conditions, trapped by a variety of nucleophilic reagents, and used to access a number of novel substituted indoles. Nucleophilic addition reactions to indolynes proceed with varying degrees of regioselectivity; distortion energies control regioselectivity and provide a simple model to predict the regioselectivity in the nucleophilic additions to indolynes and other unsymmetrical arynes. This model has led to the design of a substituted 4,5-indolyne that exhibits enhanced nucleophilic regioselectivity.

SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therepeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.